Deals In Depth: January 2014
Executive Summary
Genzyme made a significant investment in RNA interference in a new deal with Alnylam; J&J sold Ortho-Clinical Diagnostics to Carlyle Group for just over $4 billion; biopharma financing reached $2.8 billion in January, more than doubling December’s total; and device companies only raised money privately only in January, mostly from late-stage venture rounds.